397 results on '"Sakamoto, K."'
Search Results
2. List of Contributors
- Author
-
Abe, T., primary, Ando, H., additional, Ardigò, M., additional, Berardesca, E., additional, Fukui, H., additional, García-Celma, M.J., additional, Ghofranian, A., additional, Gräbner, D., additional, Grice, J., additional, Harada, F., additional, Haridass, I.N., additional, Hatao, M., additional, Hatta, I., additional, Hayase, M., additional, Herman, S., additional, Himeno, T., additional, Hirao, T., additional, Hoffmann, H., additional, Hosoi, J., additional, Huber, P., additional, Ifuku, O., additional, Inoue, S., additional, Iwata, T., additional, Joseph Lin, T, additional, Kanda, F., additional, Kikuchi, K., additional, Kishimoto, J., additional, Kitano, T., additional, Kojima, H., additional, Konno, Y., additional, Koyama, J., additional, Leite-Silva, V.R., additional, Lindman, B., additional, Lochhead, R.Y., additional, Lopes, P.S., additional, Machado, A.C.H.R., additional, Maibach, H.I., additional, Masaki, H., additional, Masuda, M., additional, Minamino, M., additional, Miyahara, R., additional, Miyake, M., additional, Nafisi, S., additional, Naito, N., additional, Nakama, Y., additional, Nakamura, N., additional, Nakazawa, Y., additional, Nikitakis, J., additional, Nonomura, Y., additional, Nozaki, F., additional, Nylander, T., additional, Oguchi-Fujiwara, N., additional, Oshimura, E., additional, Ozawa, T., additional, Raffier, C.P., additional, Roberts, M., additional, Rocafort, C.M., additional, Sakai, T., additional, Sakamoto, K., additional, Sanzone, J., additional, Solans, C., additional, Suzuki, T., additional, Tagami, H., additional, Takahashi, M., additional, Tsujii, K., additional, Uchida, Y., additional, Watanabe, K., additional, Yamashita, Y., additional, and Yang, J., additional
- Published
- 2017
- Full Text
- View/download PDF
3. Regulations on Cosmetics
- Author
-
Takahashi, M., primary and Sakamoto, K., additional
- Published
- 2017
- Full Text
- View/download PDF
4. Ultraviolet Care Cosmetics
- Author
-
Oguchi-Fujiwara, N., primary, Hatao, M., additional, and Sakamoto, K., additional
- Published
- 2017
- Full Text
- View/download PDF
5. Emulsion and Emulsification Technology
- Author
-
Yamashita, Y., primary, Miyahara, R., additional, and Sakamoto, K., additional
- Published
- 2017
- Full Text
- View/download PDF
6. Structural Analysis of Formulations
- Author
-
Yamashita, Y., primary and Sakamoto, K., additional
- Published
- 2017
- Full Text
- View/download PDF
7. The Importance of Planarity for Lipid Bilayers as Biomembranes
- Author
-
Sakamoto, K., primary
- Published
- 2016
- Full Text
- View/download PDF
8. Measurement of stray millimeter-wave radiation from a 70-GHz ECH/ECCD system in Heliotron J
- Author
-
Nagasaki, K., Watanabe, S., Sakamoto, K., Isayama, Akihiko, Okada, H., Minami, T., Kado, S., Kobayashi, S., Yamamoto, S., Ohshima, S., Konoshima, S., Mizuuchi, T., Nakamura, Y., Ishizawa, A., Kubo, S., Igami, H., Weir, G., and Marushchenko, N.
- Subjects
Physics::Plasma Physics ,Physics::Space Physics ,Astrophysics::Instrumentation and Methods for Astrophysics - Abstract
Stray millimeter-wave radiation from a 70-GHz electron cyclotron heating and current drive (ECH/ECCD) system has been measured in the Heliotron J helical device. Two rotatable diode detectors located at the out- board side ports are used to pick up the stray radiation: one is installed at the ECH launcher port and the other is installed at a toroidal angle of 135 deg far from the ECH launcher port. Both detectors are rotated to measure the polarization of the stray radiation. The results show that at the toroidal position far from the ECH launcher, the polarization is not fully randomized before plasma breakdown, whereas the polarization is uniform after a quasi- stationary plasma is generated. The polarization near the ECH launcher is not uniform even in a quasi-stationary plasma. Plasma experiments scanning the electron density indicate that the EC power absorption estimated from the stray radiation at the toroidal position far from the ECH launcher is correlated with the single-pass ab- sorption rate calculated by the TRAVIS ray-tracing code. These results indicate that the diagnostic using a simple diode detector can be used as a real-time monitor of EC power absorption only when the plasma with finite density is produced and the detector is placed far from the ECH launcher port.
- Published
- 2019
9. Status and future developments of the Linear IFMIF Prototype Accelerator (LIPAc)
- Author
-
Dzitko, H., Cara, P., Carin, Y., Chel, S., Facco, A., Gex, D., Kazuo, Hasegawa, Atsushi, Kasugai, Keitaro, Kondo, Massaut, V., Molla, J., Phillips, G., Pisent, A., Sakamoto, K., Sugimoto, M., Keishi, Sakamoto, Masayoshi, Sugimoto, Dzitko, H., Cara, P., Carin, Y., Chel, S., Facco, A., Gex, D., Kazuo, Hasegawa, Atsushi, Kasugai, Keitaro, Kondo, Massaut, V., Molla, J., Phillips, G., Pisent, A., Sakamoto, K., Sugimoto, M., Keishi, Sakamoto, and Masayoshi, Sugimoto
- Abstract
LIPAc is the Linear IFMIF Prototype Accelerator developed within the framework of the IFMIF project under the Broader Approach (BA) agreement signed between EURATOM and the Japanese Government in 2007. The IFMIF accelerator aims to provide an accelerator-based D-Li neutron source to produce high intensity neutron fluxes with appropriate energy spectrum in order to characterize materials envisioned for future fusion reactors. Because the IFMIF accelerator has to reach unprecedented performances, the feasibility is being tested through the design, manufacturing, installation, commissioning and testing activities of a 1:1-scale prototype accelerator, namely LIPAc, from the injector to the first cryomodule together with the High Energy Beam Transport line and the High Power Beam Dump. After outstanding results obtained in 2019, the LIPAc project has entered 2020 in the preparation of the third commissioning stage, i.e., validation in continuous-wave mode of the complete accelerator up to 5 MeV with its final beam dump. The validation until the nominal energy of 9 MeV will be made after the completion of cryomodule assembly. After a brief overview of the goals already achieved in the framework of the IFMIF/EVEDA program, this paper will present a synthesis of the results that have been obtained so far with the LIPAc accelerator as well as the future developments planned beyond 2020.
- Published
- 2021
10. Development of new turbocharger technologies for energy efficiency and low emissions
- Author
-
Ono, Y., primary, Shiraishi, K., additional, Sakamoto, K., additional, and Ito, Y., additional
- Published
- 2012
- Full Text
- View/download PDF
11. Pathologic Response of the Gastrointestinal Tract to Toxicants
- Author
-
Sakamoto, K., primary
- Published
- 2010
- Full Text
- View/download PDF
12. DEVELOPMENT OF A MOBILITY AID FOR THE VISUALLY IMPAIRED USING A HAPTIC FORCE GENERATOR
- Author
-
Ikeda, T., primary, Matsuda, H., additional, Shiota, Y., additional, Sakamoto, K., additional, and Shimizu, Y., additional
- Published
- 2007
- Full Text
- View/download PDF
13. SURFACE ANALYSIS | Low-Energy Electron Diffraction
- Author
-
Sakamoto, K., primary
- Published
- 2005
- Full Text
- View/download PDF
14. Study of millimeter wave high-power gyrotron for long pulse operation
- Author
-
Kasugai, A., primary, Sakamoto, K., additional, Minami, R., additional, Takahashi, K., additional, and Imai, T., additional
- Published
- 2004
- Full Text
- View/download PDF
15. Formation of Chiral Aggregates of Acylamino Acids in Organic Solvents
- Author
-
Matsuzawa, H., primary, Minami, H., additional, Yano, T., additional, Wakabayashi, T., additional, Iwahashi, M., additional, Sakamoto, K., additional, and Kaneko, D., additional
- Published
- 2001
- Full Text
- View/download PDF
16. Development of 170GHz long pulse gyrotron with depressed collector
- Author
-
Kasugai, A., primary, Sakamoto, K., additional, Tsuneoka, M., additional, Takahashi, K., additional, Maebara, S., additional, Imai, T., additional, Kariya, T., additional, Hayashi, K., additional, Mitsunaka, Y., additional, and Hirata, Y., additional
- Published
- 1997
- Full Text
- View/download PDF
17. List of participants
- Author
-
Abe, M., primary, Abo, M., additional, Abukawa, T., additional, Adachi, J., additional, Agui, A., additional, Aita, O., additional, Aiura, Y., additional, Ajello, J., additional, Akaki, O., additional, Akazawa, H., additional, Aksela, H., additional, Aksela, S., additional, Allen, J., additional, Altun, Z., additional, Amemiya, K., additional, Amusia, M., additional, An, K., additional, Andersen, J., additional, Aoki, S., additional, Arakawa, I., additional, Araki, T., additional, Arp, U., additional, Asensio, M., additional, Awaya, Y., additional, Awazu, K., additional, Azuma, H., additional, Azuma, Y., additional, Baba, Y., additional, Bando, H., additional, Bao, Z., additional, Becker, U., additional, Bengtsson, P., additional, Bobashev, S., additional, Bocquet, A., additional, Breton, J., additional, Cai, Y., additional, Caldwell, C., additional, Cauletti, C., additional, Chainani, A., additional, Che, J., additional, Chen, C., additional, Chen, L., additional, Chen, X., additional, Cherepkov, N., additional, Cho, T., additional, Christou, C., additional, Chung, J., additional, Couprie, M., additional, Cramer, S., additional, Da Silva, L., additional, Daimon, H., additional, Deguchi, K., additional, Dessau, D., additional, Dhanak, V., additional, Dolmatov, V., additional, Drube, W., additional, Echigo, S., additional, Ehresmann, A., additional, Eisebitt, S., additional, Ejima, T., additional, Ejiri, A., additional, Endo, O., additional, England, J., additional, Enta, Y., additional, Fadley, C., additional, Feldhaus, J., additional, Filatova, E., additional, Finazzi, M., additional, Finkenthal, M., additional, Fischer, D., additional, Flechsig, U., additional, Franzén, K., additional, Frasinski, L., additional, Fujikawa, T., additional, Fujimori, A., additional, Fujimori, S., additional, Fujisawa, M., additional, Fujita, K., additional, Fujita, M., additional, Fukui, K., additional, Fukutani, H., additional, Ghijsen, J., additional, Gluskin, E., additional, Guo, Q., additional, Guyon, P., additional, Hague, C., additional, Hall, R., additional, Hamamatsu, H., additional, Han, Z., additional, Hansen, J., additional, Hanyu, T., additional, Happo, N., additional, Hara, T., additional, Harada, I., additional, Harada, Y., additional, Hasegawa, M., additional, Hasegawa, S., additional, Hatano, T., additional, Hatherly, P., additional, Hattori, T., additional, Hayaishi, T., additional, Hayasi, T., additional, Heck, C., additional, Heinzmann, U., additional, Hieda, K., additional, Higashiyama, K., additional, Hirai, Y., additional, Hiraya, A., additional, Hirayama, T., additional, Hirose, S., additional, Hishikawa, A., additional, Hopkirk, A., additional, Horikawa, Y., additional, Hosaka, N., additional, Huber, K., additional, Huff, W., additional, Hussain, Z., additional, Hwang, C., additional, Ibrahim, K., additional, Ibuki, T., additional, Ichikawa, K., additional, Ichikawa, M., additional, Igarashi, J., additional, Iguchi, Y., additional, Iimura, K., additional, Iinuma, D., additional, Iketaki, Y., additional, Ikeura, H., additional, Imada, S., additional, Imaizumi, Y., additional, Imanishi, A., additional, Inokuchi, H., additional, Inoue, I., additional, Ishigame, M., additional, Ishiguro, E., additional, Ishii, H., additional, Ishii, T., additional, Ishijima, H., additional, Ishizue, I., additional, Isoyama, G., additional, Ito, K., additional, Itoh, M., additional, Itoh, Y., additional, Iwami, M., additional, Iwano, K., additional, Iwasaki, K., additional, Iwata, S., additional, Jacobsen, C., additional, Jikimoto, T., additional, Jo, T., additional, Johansson, L., additional, Johansson, U., additional, Jouda, K., additional, Jung, C., additional, Kabachnik, N., additional, Kaindl, G., additional, Kakizaki, A., additional, Kamada, M., additional, Kamata, A., additional, Kamenskikh, I., additional, Kameta, K., additional, Kamiya, K., additional, Kamiya, Y., additional, Kan'no, K., additional, Kanomata, T., additional, Kasaya, M., additional, Kashiwakura, T., additional, Kato, R., additional, Kato, Y., additional, Katoh, R., additional, Kaurila, T., additional, Kawai, J., additional, Kawamura, T., additional, Kayanuma, Y., additional, Kaznacheyev, K., additional, Kennedy, E., additional, Kiguchi, M., additional, Kihara, H., additional, Kimpara, Y., additional, Kimura, A., additional, Kimura, H., additional, Kimura, K., additional, Kimura, S., additional, Kinoshita, T., additional, Kirm, M., additional, Kisker, E., additional, Kitade, T., additional, Kitajima, M., additional, Kitajima, Y., additional, Kitamura, H., additional, Kitaura, M., additional, Kobayashi, K., additional, Kobayashi, M., additional, Koda, T., additional, Kohagura, J., additional, Koide, T., additional, Koike, F., additional, Koike, M., additional, Koike, T., additional, Koizumi, T., additional, Kojima, T., additional, Kondo, K., additional, Kondo, Y., additional, Kono, M., additional, Kono, S., additional, Korde, R., additional, Koseki, T., additional, Kosugi, N., additional, Kotani, A., additional, Kotani, M., additional, Kouchi, N., additional, Kowalski, M., additional, Koyama, M., additional, Koyano, I., additional, Krause, M., additional, Krupa, J., additional, Kumigashira, H., additional, Kuninobu, T., additional, Kurita, S., additional, Kusaka, M., additional, Kutluk, G., additional, Lablanquie, P., additional, Lama, F., additional, Larkins, F., additional, Latimer, C., additional, Lebrun, T., additional, Lee, D., additional, Lee, K., additional, Lee, T., additional, Legrand, F., additional, Lewis, B., additional, Li, D., additional, Lindau, I., additional, Liu, F., additional, Lodha, G., additional, Lu, E., additional, Lushchik, A., additional, Lyakhovskaya, I., additional, Mårtensson, N., additional, Ma, Y., additional, Machida, S., additional, Maeda, F., additional, Maeyama, S., additional, Maezawa, H., additional, Manakov, N., additional, Margaritondo, G., additional, Masui, S., additional, Masuoka, T., additional, Matsui, F., additional, Matsukawa, T., additional, Matsumoto, M., additional, Matsumoto, S., additional, Matsushita, T., additional, Matsuzawa, M., additional, Mattogno, G., additional, Messina, A., additional, Mikhailin, V., additional, Mimura, K., additional, Minami, T., additional, Misu, A., additional, Mitsuishi, T., additional, Mitsuke, K., additional, Mitsumoto, R., additional, Miyahara, T., additional, Miyamae, T., additional, Miyamoto, N., additional, Miyauchi, H., additional, Mizokawa, T., additional, Morgan, H., additional, Mori, I., additional, Mori, T., additional, Morin, P., additional, Morioka, Y., additional, Mosnier, J., additional, Munro, I., additional, Murakami, E., additional, Murata, T., additional, Murata, Y., additional, Muro, T., additional, Nagakura, I., additional, Nagaoka, S., additional, Nagata, T., additional, Nahon, L., additional, Nakagawa, K., additional, Nakai, I., additional, Nakai, S., additional, Nakai, Y., additional, Nakaishi, H., additional, Nakajima, N., additional, Nakamura, H., additional, Nakamura, M., additional, Nakatake, M., additional, Nakazawa, M., additional, Namatame, H., additional, Namioka, T., additional, Nanba, T., additional, Naoe, S., additional, Nasu, K., additional, Neeb, M., additional, Nenner, I., additional, Nishihara, Y., additional, Nishioka, H., additional, Niwano, M., additional, Nordgren, J., additional, Norman, D., additional, Nowak, C., additional, Nyholm, R., additional, Nylén, H., additional, Ogasawara, H., additional, Ogata, T., additional, Oh, S., additional, Ohara, J., additional, Ohashi, H., additional, Ohchi, T., additional, Ohmori, K., additional, Ohnishi, A., additional, Ohno, N., additional, Ohta, T., additional, Oji, H., additional, Okada, K., additional, Okajima, T., additional, Okane, T., additional, Okuda, T., additional, Okunishi, M., additional, Okusawa, M., additional, Olson, C., additional, Onellion, M., additional, Ono, I., additional, Ono, K., additional, Onsgaard, J., additional, Onuki, H., additional, Oshima, M., additional, Ouchi, I., additional, Ouchi, Y., additional, Oura, M., additional, Park, C., additional, Park, S., additional, Perera, R., additional, Petroff, Y., additional, Poliakoff, E., additional, Pong, W., additional, Prabhakaran, K., additional, Pratt, R., additional, Qvarford, M., additional, Rader, O., additional, Rahn, S., additional, Randall, K., additional, Reininger, R., additional, Rosenberg, R., additional, Rubensson, J., additional, Sainctavit, P., additional, Saito, N., additional, Saito, T., additional, Saitoh, T., additional, Saitoh, Y., additional, Sakamoto, K., additional, Sakano, M., additional, Sakisaka, Y., additional, Samson, J., additional, Sarma, D., additional, Sasaki, T., additional, Sasano, T., additional, Sato, H., additional, Sato, N., additional, Sato, S., additional, Sato, Y., additional, Savchenko, E., additional, Schattke, W., additional, Schlachter, F., additional, Schmidt, V., additional, Schwentner, N., additional, Seki, K., additional, Sekiguchi, T., additional, Sekitani, T., additional, Sekiyama, A., additional, Seno, H., additional, Shafi, M., additional, Sham, T., additional, Sheng, L., additional, Shi, C., additional, Shidara, T., additional, Shigemasa, E., additional, Shimada, H., additional, Shimada, K., additional, Shimamura, I., additional, Shimizu, Y., additional, Shimoyama, I., additional, Shin, S., additional, Shiraga, H., additional, Shirai, M., additional, Shishidou, T., additional, Shmaenok, L., additional, Shobatake, K., additional, Simon, M., additional, Smith, N., additional, Soda, K., additional, Solov'yov, A., additional, Sonntag, B., additional, Spanke, D., additional, Stankevitch, V., additional, Steinberger, I., additional, Steiner, P., additional, Suga, S., additional, Sugawara, H., additional, Sutherland, D., additional, Suzuki, I., additional, Suzuki, M., additional, Suzuki, N., additional, Suzuki, S., additional, Suzuki, T., additional, Taguchi, Y., additional, Takahashi, N., additional, Takahashi, T., additional, Takakuwa, Y., additional, Takata, Y., additional, Takatsuchi, K., additional, Takeichi, A., additional, Takenaka, H., additional, Takizawa, Y., additional, Tanaka, A., additional, Tanaka, K., additional, Tanaka, M., additional, Tanaka, S., additional, Tanaka, T., additional, Tang, J., additional, Tani, K., additional, Taniguchi, M., additional, Tayu, T., additional, Terada, S., additional, Terminello, L., additional, Tezuka, H., additional, Tezuka, Y., additional, Thissen, R., additional, Tinone, M., additional, Tokue, I., additional, Tonner, B., additional, Toyota, E., additional, Troussel, P., additional, Ueda, K., additional, Ueda, Y., additional, Ueno, N., additional, Uhrberg, R., additional, Ukai, M., additional, Umehara, T., additional, Uozumi, T., additional, Urisu, T., additional, Vaeterlein, P., additional, Van der Laan, G., additional, Van Hove, M., additional, Viane, P., additional, Voss, J., additional, Wang, X., additional, Watanabe, M., additional, Watanabe, N., additional, Watanabe, Y., additional, Weaver, J., additional, West, J., additional, van Wezenbeek, E., additional, Whitfield, S., additional, Woodruff, D., additional, Wu, L., additional, Wu, R., additional, Xu, P., additional, Xu, W., additional, Yagi, K., additional, Yagi, S., additional, Yagishita, A., additional, Yamada, T., additional, Yamakawa, T., additional, Yamamoto, H., additional, Yamamoto, M., additional, Yamamoto, Y., additional, Yamanaka, T., additional, Yamanouchi, K., additional, Yamashita, K., additional, Yanagihara, M., additional, Yang, S., additional, Yang, Y., additional, Yeom, H., additional, Yimagawa, M., additional, Ynzunza, R., additional, Yokoya, T., additional, Yokoyama, T., additional, Yoshida, A., additional, Yoshida, H., additional, Yoshi, K., additional, Yoshimura, D., additional, Yuri, M., additional, Zama, T., additional, Zeitoun, P., additional, Zhang, X., additional, Zhang, Y., additional, Zimmerer, G., additional, and Zimmermann, R., additional
- Published
- 1996
- Full Text
- View/download PDF
18. Development of high power gyrotron with energy recovery system
- Author
-
Sakamoto, K., primary, Tsuneoka, M., additional, Kasugai, A., additional, Takahashi, K., additional, Maebara, S., additional, Imai, T., additional, Kariya, T., additional, Okazaki, Y., additional, Hayashi, K., additional, Mitsunaka, Y., additional, and Hirata, Y., additional
- Published
- 1995
- Full Text
- View/download PDF
19. FUNDAMENTAL AND PHASE I CLINICAL STUDY OF NEW HYPOXIC RADIOSENSITIZER RK-28
- Author
-
NEMOTO, K., primary, SAKAMOTO, K., additional, OGAWA, Y., additional, TAKAI, Y., additional, YAMADA, S., additional, MATSUMOTO, S., additional, MIYATA, Y., additional, and SAKAGUCHI, M., additional
- Published
- 1991
- Full Text
- View/download PDF
20. POSSIBILITY OF JUMP PHENOMENA FROM OPERABLE LOAD FLOW SOLUTION TO NONOPERABLE SOLUTION BY THE IMPACT OF SWITCHING-IN OF SHUNT CAPACITOR BANKS
- Author
-
Tamura, Y., primary, Tayama, Y., additional, Sakamoto, K., additional, Nakanishi, Y., additional, and Yokokawa, S., additional
- Published
- 1990
- Full Text
- View/download PDF
21. Exercise-induced molecular mechanisms promoting glycogen supercompensation in human skeletal muscle
- Author
-
Hingst, JR, Bruhn, L, Hansen, MB, Rosschou, MF, Birk, JB, Fentz, J, Foretz, M, Viollet, B, Sakamoto, K, Faergeman, NJ, Havelund, JF, Parker, BL, James, DE, Kiens, B, Richter, EA, Jensen, J, Wojtaszewski, JFP, Hingst, JR, Bruhn, L, Hansen, MB, Rosschou, MF, Birk, JB, Fentz, J, Foretz, M, Viollet, B, Sakamoto, K, Faergeman, NJ, Havelund, JF, Parker, BL, James, DE, Kiens, B, Richter, EA, Jensen, J, and Wojtaszewski, JFP
- Abstract
OBJECTIVE: A single bout of exercise followed by intake of carbohydrates leads to glycogen supercompensation in prior exercised muscle. Our objective was to illuminate molecular mechanisms underlying this phenomenon in skeletal muscle of man. METHODS: We studied the temporal regulation of glycogen supercompensation in human skeletal muscle during a 5 day recovery period following a single bout of exercise. Nine healthy men depleted (day 1), normalized (day 2) and supercompensated (day 5) muscle glycogen in one leg while the contralateral leg served as a resting control. Euglycemic hyperinsulinemic clamps in combination with leg balance technique allowed for investigating insulin-stimulated leg glucose uptake under these 3 experimental conditions. Cellular signaling in muscle biopsies was investigated by global proteomic analyses and immunoblotting. We strengthened the validity of proposed molecular effectors by follow-up studies in muscle of transgenic mice. RESULTS: Sustained activation of glycogen synthase (GS) and AMPK in combination with elevated expression of proteins determining glucose uptake capacity were evident in the prior exercised muscle. We hypothesize that these alterations offset the otherwise tight feedback inhibition of glycogen synthesis and glucose uptake by glycogen. In line with key roles of AMPK and GS seen in the human experiments we observed abrogated ability for glycogen supercompensation in muscle with inducible AMPK deletion and in muscle carrying a G6P-insensitive form of GS in muscle. CONCLUSION: Our study demonstrates that both AMPK and GS are key regulators of glycogen supercompensation following a single bout of glycogen-depleting exercise in skeletal muscle of both man and mouse.
- Published
- 2018
22. Metformin selectively targets redox control of complex I energy transduction
- Author
-
Cameron, A. R. (Amy R.), Logie, L. (Lisa), Patel, K. (Kashyap), Erhardt, S. (Stefan), Bacon, S. (Sandra), Middleton, P. (Paul), Harthill, J. (Jean), Forteath, C. (Calum), Coats, J. T. (Josh T.), Kerr, C. (Calum), Curry, H. (Heather), Stewart, D. (Derek), Sakamoto, K. (Kei), Repiščák, P. (Peter), Paterson, M. J. (Martin J.), Hassinen, I. (Ilmo), McDougall, G. (Gordon), Rena, G. (Graham), Cameron, A. R. (Amy R.), Logie, L. (Lisa), Patel, K. (Kashyap), Erhardt, S. (Stefan), Bacon, S. (Sandra), Middleton, P. (Paul), Harthill, J. (Jean), Forteath, C. (Calum), Coats, J. T. (Josh T.), Kerr, C. (Calum), Curry, H. (Heather), Stewart, D. (Derek), Sakamoto, K. (Kei), Repiščák, P. (Peter), Paterson, M. J. (Martin J.), Hassinen, I. (Ilmo), McDougall, G. (Gordon), and Rena, G. (Graham)
- Abstract
Many guanide-containing drugs are antihyperglycaemic but most exhibit toxicity, to the extent that only the biguanide metformin has enjoyed sustained clinical use. Here, we have isolated unique mitochondrial redox control properties of metformin that are likely to account for this difference. In primary hepatocytes and H4IIE hepatoma cells we found that antihyperglycaemic diguanides DG5-DG10 and the biguanide phenformin were up to 1000-fold more potent than metformin on cell signalling responses, gluconeogenic promoter expression and hepatocyte glucose production. Each drug inhibited cellular oxygen consumption similarly but there were marked differences in other respects. DG5 and phenformin but not metformin inhibited NADH oxidation in submitochondrial particles, indicative of complex I inhibition, which also corresponded closely with dehydrogenase activity in living cells measured by WST-1. Consistent with these findings, in isolated mitochondria, DG8 but not metformin caused the NADH/NAD+ couple to become more reduced over time and mitochondrial deterioration ensued, suggesting direct inhibition of complex I and mitochondrial toxicity of DG8. In contrast, metformin exerted a selective oxidation of the mitochondrial NADH/NAD+ couple, without triggering mitochondrial deterioration. Together, our results suggest that metformin suppresses energy transduction by selectively inducing a state in complex I where redox and proton transfer domains are no longer efficiently coupled.
- Published
- 2018
23. Growth of oxide particles in FeCrAl- oxide dispersion strengthened steels at high temperature
- Author
-
Oono, N.H., Ukai, S., Hayashi, S., Ohtsuka, S., Kaito, T., Kimura, A., Torimaru, T., Sakamoto, K., Oono, N.H., Ukai, S., Hayashi, S., Ohtsuka, S., Kaito, T., Kimura, A., Torimaru, T., and Sakamoto, K.
- Abstract
The growth of oxide particles in FeCrAl-oxide dispersion strengthened steel (ODSS) considering an accident condition of the light-water reactor at above 1500 K was studied by using a high-temperature annealing. Oxide particles grew from 9 nm to more than 50 nm as maximum at 1623 K for 27 h, with decreasing their number density in two orders of magnitude. Most of the oxide particles in 15Cr-7Al were identified as YAM or YAP, while the oxide particles in 15Cr-7Al-0.4Zr were identified trigonal Y4Zr3O12. Zr addition to 15Cr-7Al ODSS accelerated the growth of the oxide particles, which is quite contrary to the effect of Zr addition during sintering as suggested in the literature. The kinetics of coarsening was characterized by an equation of Ostwald ripening. The diffusion activation energies obtained in the present materials were quite larger than the conventional diffusion activation energy of Y in alpha-iron. Gibbs free energy of oxides should be considered to discuss the coarsening. (C) 2017 Elsevier B.V. All rights reserved.
- Published
- 2017
24. PRELIMINARY RESULTS OF TEST STAND EXPERIMENT OF LHRF LAUNCHER
- Author
-
Fujii, T., primary, Sakamoto, K., additional, Uehara, K., additional, Imai, T., additional, Honda, M., additional, and Nagashima, T., additional
- Published
- 1982
- Full Text
- View/download PDF
25. HEPATOTOXICITY AND SURFACE ACTIVITY OF PSYCHOACTIVE DRUGS
- Author
-
Dujovne, C., primary, Yasuhara, H., additional, Salhab, A., additional, and Sakamoto, K., additional
- Published
- 1978
- Full Text
- View/download PDF
26. A PROPOSAL OF INTELLIGENT MONITORING AND ALARMING FOR MW & MVAR STABILITIES IN POWER SYSTEMS
- Author
-
Tamura, Y., primary, Satake, K., additional, Nakazawa, T., additional, Isoda, K., additional, Hashimoto, J., additional, Sakamoto, K., additional, Yorino, N., additional, Sasaki, H., additional, and Kubo, K., additional
- Published
- 1989
- Full Text
- View/download PDF
27. Effects of indium doping on the superconducting properties of YBa2Cu3Oy sintered compounds and thin films
- Author
-
Kita Ryusuke, Nakamura S., Sakamoto K., Nakamura T., Miura O., Matsumoto K., Mele P., Yamada K., Kaneko K., Ichinose A., Kita Ryusuke, Nakamura S., Sakamoto K., Nakamura T., Miura O., Matsumoto K., Mele P., Yamada K., Kaneko K., and Ichinose A.
- Published
- 2010
28. Polarizers with non-rectangular grooves for high power millimeter waves
- Author
-
Nagasaki, Kazunobu, Itoh, Y., Sakamoto, K, Obiki, T, Maekawa, T, Morioka, H, Terumichi, T, Asakawa, M., Shats, Michael, Punzmann, Horst, Nagasaki, Kazunobu, Itoh, Y., Sakamoto, K, Obiki, T, Maekawa, T, Morioka, H, Terumichi, T, Asakawa, M., Shats, Michael, and Punzmann, Horst
- Abstract
Polarizers with non-rectangular grooves are studied in high power millimeter wave transmission lines for electron cyclotron heating (ECH) and electron cyclotron current drive (ECCD) of fusion plasmas. The groove shape is important for determining the polarization parameters and avoiding arc breakdown in the system. A low-power measurement has been carried out for several polarizers with different groove depths. The polarization characteristics experimentally measured are in good agreement with numerical results in which the actual groove shape is taken into account. The polarizers are designed and applied to different frequencies of ECH/ECCD systems. Favorable results have been obtained in high-power transmission up to 500 kW, 0.2 s.
- Published
- 2001
29. The small GTPase RAB-18 is involved in regulating development/diapause by recruiting the intestinal cholesterol transporter NCR-1 onto the apical side in Caenorhabditis elegans.
- Author
-
Awazu T, Sakamoto K, Minagi Y, Ohnishi M, Bito T, Matsunaga Y, Iwasaki T, and Kawano T
- Subjects
- Animals, Intestinal Mucosa metabolism, RNA Interference, Intestines, Caenorhabditis elegans metabolism, Caenorhabditis elegans genetics, rab GTP-Binding Proteins metabolism, rab GTP-Binding Proteins genetics, Caenorhabditis elegans Proteins metabolism, Caenorhabditis elegans Proteins genetics, Cholesterol metabolism
- Abstract
RAB family proteins, which are small GTPases, are integral to the process of eukaryotic membrane trafficking. In the nematode, Caenorhabditis elegans, 31 RAB proteins have been identified through genome sequencing. Using an RNAi screen specifically targeting C. elegans rab genes, we identified multiple genes that are involved in the regulation of larval development, in particular, the rab-18 gene. Our molecular genetic studies resulted in several findings. First, RAB-18 predominantly functions in the intestine to regulate larval development by modulating steroid hormone signaling. Second, the C. elegans cholesterol transporter NCR-1 is a target of RAB-18 in the intestine. Third, the membrane trafficking of NCR-1 to the apical side in intestinal cells is particularly influenced by RAB-18. Finally, RAB-18 and NCR-1 possibly co-localize on membrane vesicles. Our study is the first to demonstrate the relationship between a RAB protein and a cholesterol transporter, in which the RAB protein probably drives the transporter to the apical membrane in the intestine to regulate cholesterol uptake. This study provides insight into the molecular mechanisms underlying human disease stemming from a transport defect of cholesterol and its derivative., Competing Interests: Declaration of competing interest All authors declare no potential conflict of interest., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.
- Author
-
Miyamoto S, Heerspink HJL, de Zeeuw D, Sakamoto K, Yoshida M, Toyoda M, Suzuki D, Hatanaka T, Nakamura T, Kamei S, Murao S, Hida K, Ando S, Akai H, Takahashi Y, Kitada M, Sugano H, Nunoue T, Nakamura A, Sasaki M, Nakatou T, Fujimoto K, Kawanami D, Wada T, Miyatake N, Kuramoto H, and Shikata K
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Treatment Outcome, Creatinine urine, Canagliflozin therapeutic use, Glomerular Filtration Rate drug effects, Albuminuria drug therapy, Albuminuria diagnosis, Albuminuria urine, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 physiopathology, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Renal Insufficiency, Chronic drug therapy, Renal Insufficiency, Chronic physiopathology, Renal Insufficiency, Chronic urine, Diabetic Nephropathies drug therapy, Diabetic Nephropathies diagnosis, Diabetic Nephropathies urine, Diabetic Nephropathies physiopathology, Diabetic Nephropathies etiology, Disease Progression
- Abstract
Demonstrating drug efficacy in slowing kidney disease progression requires large clinical trials when targeting participants with an early stage of chronic kidney disease (CKD). In this randomized, parallel-group, open-labeled trial (CANPIONE study), we assessed the effect of the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin using the individual's change in estimated glomerular filtration rate (eGFR) slope before (pre-intervention slope) and during treatment (chronic slope). We randomly assigned (1:1) participants with type 2 diabetes, urinary albumin-to-creatinine ratio (UACR) of 50 to under 300 mg/g, and an eGFR of at least 45 ml/min/1.73m
2 to receive canagliflozin or guideline-recommended treatment except for SGLT2 inhibitors (control). The first and second primary outcomes were the geometric mean percentage change from baseline in UACR and the change in eGFR slope, respectively. Of 98 randomized participants, 96 received at least one study treatment. The least-squares mean change from baseline in log-transformed geometric mean UACR was significantly greater in the canagliflozin group than the control group (between group-difference, -30.8% (95% confidence interval -42.6 to -16.8). The between-group difference (canagliflozin group - control group) of change in eGFR slope (chronic - pre-intervention) was 4.4 (1.6 to 7.3) ml/min/1.73 m2 per year, which was more pronounced in participants with faster eGFR decline. In summary, canagliflozin reduced albuminuria and the participant-specific natural course of eGFR decline in participants with type 2 diabetes and microalbuminuria. Thus, the CANPIONE study suggests that the within-individual change in eGFR slope may be a novel approach to determine the kidney protective potential of new therapies in early stages of CKD., (Copyright © 2024 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
31. Expression pattern of Runt-related transcription factor (RUNX) family members and the role of RUNX1 during kidney development.
- Author
-
Yano-Sakamoto K, Kitai Y, Toriu N, Yamamoto S, Mizuta K, Saitou M, Tsukiyama T, Taniuchi I, Osato M, and Yanagita M
- Subjects
- Animals, Mice, Macaca fascicularis, Gene Expression Regulation, Developmental, Core Binding Factor Alpha 1 Subunit metabolism, Core Binding Factor Alpha 1 Subunit genetics, Core Binding Factor Alpha 3 Subunit metabolism, Core Binding Factor Alpha 3 Subunit genetics, Core Binding Factor alpha Subunits metabolism, Core Binding Factor alpha Subunits genetics, Mice, Inbred C57BL, Mice, Knockout, Core Binding Factor Alpha 2 Subunit metabolism, Core Binding Factor Alpha 2 Subunit genetics, Kidney metabolism, Kidney embryology, Kidney growth & development
- Abstract
Runt-related transcription factor (RUNX) family members play critical roles in the development of multiple organs. Mammalian RUNX family members, consisting of RUNX1, RUNX2, and RUNX3, have distinct tissue-specific expression and function. In this study, we examined the spatiotemporal expression patterns of RUNX family members in developing kidneys and analyzed the role of RUNX1 during kidney development. In the developing mouse kidney, RUNX1 protein was strongly expressed in the ureteric bud (UB) tip and weakly expressed in the distal segment of the renal vesicle (RV), comma-shaped body (CSB), and S-shaped body (SSB). In contrast, RUNX2 protein was restricted to the stroma, and RUNX3 protein was only expressed in immune cells. We also analyzed the expression of RUNX family members in the cynomolgus monkey kidney. We found that expression patterns of RUNX2 and RUNX3 were conserved between rodents and primates, whereas RUNX1 was only expressed in the UB tip, not in the RV, CSB, or SSB of cynomolgus monkeys, suggesting a species differences. We further evaluated the roles of RUNX1 using two different conditional knockout mice: Runx1
f/f :HoxB7-Cre and Runx1f/f :R26-CreERT2 and found no abnormalities in the kidney. Our findings showed that RUNX1, which is mainly expressed in the UB tip, is not essential for kidney development., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Motoko Yanagita reports financial support was provided by Japan Agency for Medical Research and Development. Motoko Yanagita reports a relationship with Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim that includes: funding grants. None has patent pending to none. none If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
32. Oleanolic acid-3-glucoside, a synthetic oleanane-type saponin, ameliorates methylmercury-induced dysfunction of synaptic transmission in mice.
- Author
-
Nakamura R, Iwai T, Takanezawa Y, Shirahata T, Konishi N, Ohshiro Y, Uraguchi S, Tanabe M, Kobayashi Y, Sakamoto K, Nakahara T, Yamamoto M, and Kiyono M
- Subjects
- Animals, Male, Mice, Glucosides pharmacology, Purkinje Cells drug effects, Purkinje Cells pathology, Cerebellum drug effects, Cerebellum pathology, Cerebellum metabolism, Motor Activity drug effects, Mice, Inbred ICR, Methylmercury Compounds toxicity, Oleanolic Acid pharmacology, Oleanolic Acid analogs & derivatives, Synaptic Transmission drug effects, Saponins pharmacology
- Abstract
Methylmercury (MeHg) is widely distributed in nature and is known to cause neurotoxic effects. This study aimed to examine the anti-MeHg activity of oleanolic acid-3-glucoside (OA3Glu), a synthetic oleanane-type saponin derivative, by evaluating its effects on motor function, pathology, and electrophysiological properties in a mouse model of MeHg poisoning. Mice were orally administered 2 or 4 mg·kg
-1 ·d-1 MeHg with or without 100 µg·kg-1 ·d-1 OA3Glu 5x/week for four weeks. Motor function was evaluated using beam-walking and dynamic weight-bearing (DWB) tests. High-dose MeHg exposure significantly increased the frequency of stepping off the hind leg while crossing the beam in the beam-walking test, and increased weight on forelegs when moving freely in the DWB test. OA3Glu treatment alleviated motor abnormality caused by high-dose MeHg exposure in both motor function tests. Additionally, OA3Glu treatment reduced the number of contracted Purkinje cells frequently observed in the cerebellum of MeHg-treated groups, although cerebrum histology was similar in all experimental groups. The synaptic potential amplitude in the cerebellum decreased as MeHg exposure increased, which was restored by OA3Glu treatment. Even in the cerebrum, where the effects of MeHg were not observed, the amplitude of the field potential was suppressed with increasing MeHg exposure but was restored with OA3Glu treatment. Taken together, the study findings suggest that OA3Glu improves neurotransmission and movement disorders associated with MeHg exposure via protection of Purkinje cells in the cerebellum while ameliorating pre/post-synaptic deficits in the cerebral cortex in which no changes were observed at the tissue level, potentially providing a treatment to mitigate MeHg toxicity., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
33. Robot assisted anatomical liver resection is safe for patient with hepatocellular carcinoma underlying Fontan-associated liver disease.
- Author
-
Oğuzhan Ş, Sakamoto K, Tamura K, Honjo M, Nishi Y, Funamizu N, Ogawa K, and Takada Y
- Published
- 2024
- Full Text
- View/download PDF
34. Diagnostic yields and safety of thoracoscopic cryobiopsies in Japan: A single-center retrospective observational study.
- Author
-
Kamatani M, Awano N, Inomata M, Kuse N, Sakamoto K, Kumasaka T, and Izumo T
- Subjects
- Humans, Retrospective Studies, Male, Female, Aged, Biopsy methods, Biopsy adverse effects, Japan, Middle Aged, Aged, 80 and over, Pleural Neoplasms diagnosis, Pleural Neoplasms pathology, Mesothelioma, Malignant diagnosis, Mesothelioma, Malignant pathology, Adult, Thoracoscopy methods, Thoracoscopy adverse effects, Lung Neoplasms diagnosis, Lung Neoplasms pathology, Pleural Effusion etiology, Pleural Effusion pathology
- Abstract
Background: Thoracoscopy is useful for diagnosing unexplained pleural effusions. A sufficient specimen volume is often difficult to obtain using forceps biopsies (FBs) but can be obtained with pleural cryobiopsies (CBs). This study aimed to assess the utility and safety of CB during thoracoscopy in the Japanese population., Methods: Patients who underwent thoracoscopic CBs at the Japanese Red Cross Medical Center between January 2017 and August 2023 were included in the study. Data were retrospectively analyzed, including clinical data, thoracoscopic findings, specimen size, diagnostic yield, and complications. The number of collected specimens and the freezing time were left to the discretion of the attending physician., Results: Twenty-six patients underwent thoracoscopic CB. Specimens obtained by CB were larger than those obtained by FB. Primary lung cancer was the most common cause of pleural effusion, followed by malignant pleural mesothelioma. CB contributed to the diagnosis in 24 of 26 cases (92.3%) and FB contributed to the diagnosis in 11 of 18 cases (61.1%). Severe fibrosis could be diagnosed in all 3 cases by CB, but not by FB. The common complications of CB included bleeding at the biopsy site and atelectasis, but no severe complications occurred., Conclusions: The utility and safety of thoracoscopic CB for diagnosing pleural effusions in Japan were verified. The diagnostic yield, specimen size, and safety profile of CB support the diagnostic utility of this method., Competing Interests: Declaration of competing interest The authors have no conflicts of interest., (Copyright © 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
35. Efficacy and Safety of a New Delivery Assist Catheter with a Flexible, Spindle-Shaped Shaft in Mechanical Thrombectomy.
- Author
-
Takeshita S, Nii K, Tsugawa J, Ishii A, Fukumoto H, Hanada H, Inoue R, Sakamoto K, and Higashi T
- Subjects
- Humans, Male, Female, Retrospective Studies, Aged, Middle Aged, Treatment Outcome, Equipment Design, Ischemic Stroke surgery, Ischemic Stroke diagnostic imaging, Aged, 80 and over, Catheters, Thrombectomy methods, Thrombectomy instrumentation
- Abstract
Objective: Large-bore aspiration catheters (ACs) are used successfully in mechanical thrombectomy (MT). However, tortuous access routes prevent device navigation because of the ledge effect. The AXS Offset Delivery Assist Catheter is designed to reduce the ledge effect. The purpose of this study was to evaluate whether the Offset affects AC navigation compared with standard inner microcatheters in MT., Methods: We retrospectively investigated 75 MTs for anterior circulation occlusion between January 2018 and May 2022 at our hospital. All MTs were performed using an AC, and 2 types of inner microcatheter (Offset or 0.021-0.027-inch standard microcatheter) were chosen randomly during AC navigation. The patients' characteristics, MT techniques, angiographic findings, and clinical outcomes were compared between the Offset and standard group (Non-Offset). The puncture to first pass of the lesion time was investigated to compare the characteristics of the inner catheters., Results: The Offset group comprised 12 patients versus 63 in the Non-Offset group. Although most baseline clinical characteristics and outcomes were similar between the groups, the puncture to first pass of the lesion time was significantly shorter in the Offset versus Non-Offset group (31 ± 10 vs. 46 ± 24 minutes, respectively; P = 0.032). In the Offset group, all stent retrievers were deployed via the Offset. One artery dissection and 8 symptomatic intracranial hemorrhages occurred in the Non-Offset group; no complications occurred in the Offset group., Conclusions: The AXS Offset delivery assist catheter permitted faster and safer navigation of various ACs to the occlusions compared with standard delivery microcatheters in MT., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
36. Rapidly progressive interstitial lung disease with positive anti-MDA5 antibody as an immune-related complication of nivolumab: A case report.
- Author
-
Kato S, Sakamoto K, Sato T, Kobayashi T, Shindo Y, Morise M, Iwama S, Arima H, and Ishii M
- Subjects
- Humans, Autoantibodies, Interferon-Induced Helicase, IFIH1, Nivolumab adverse effects, Lung Diseases, Interstitial diagnosis, Dermatomyositis
- Abstract
Clinically amyopathic dermatomyositis (CADM) with a positive anti-MDA5 antibody titer is often associated with lethal rapidly progressive interstitial lung disease (RP-ILD). Despite the widespread use of immune checkpoint inhibitors (ICIs) in practice, there is no report of CADM with positive anti-MDA5 antibodies as their immune-related complication. We present a case of malignant mesothelioma who developed RP-ILD accompanied by distinct skin manifestations following the administration of nivolumab. Postmortem assessment of stored samples revealed a pre-existing positive titer of anti-MDA5 antibody, further augmented following ICI use, suggesting the possible value of serum screening for better risk stratification of this lethal complication., Competing Interests: Declaration of competing interest H.A. received grants from Ono Pharmaceutical Co., Ltd. unrelated to this study. M.I. received grants from Nippon Boehringer Ingelheim Co., Ltd., and personal fees from AstraZeneca K.K. and Shionogi & Co., Ltd. Unrelated to this study. The other authors declare no conflicts of interest., (Copyright © 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
37. Atelocollagen-associated autologous chondrocyte implantation for the repair of large cartilage defects of the knee: Results at three to seven years.
- Author
-
Kaibara T, Kondo E, Matsuoka M, Iwasaki K, Onodera T, Sakamoto K, Oda Y, Tanei ZI, Momma D, Tanaka S, and Iwasaki N
- Subjects
- Male, Humans, Female, Adult, Chondrocytes transplantation, Knee Joint diagnostic imaging, Knee Joint surgery, Transplantation, Autologous methods, Follow-Up Studies, Cartilage, Articular diagnostic imaging, Cartilage, Articular surgery, Cartilage, Articular injuries, Orthopedic Procedures methods, Cartilage Diseases diagnostic imaging, Cartilage Diseases surgery
- Abstract
Background: Recently, various types of engineered autologous chondrocyte implantation (ACI) have been developed. Atelocollagen-associated ACI (A-ACI) is the only ACI procedure covered by Japanese Health Insurance since 2013. The indications of the A-ACI are traumatic cartilage defects and osteochondral dissecans (OCD) for knee joints., Purpose: To evaluate midterm clinical results after A-ACI for the treatment for full-thickness cartilage defects of the knee., Methods: Thirteen consecutive patients who underwent A-ACI between 2014 and 2018 had been prospectively enrolled in this study. There were 11 men and 2 women with a mean age of 34 years at the time of surgery. The causes of the cartilage defect were trauma in 10 knees and OCD in 3 knees. The total number of lesions was 15, which were comprised of the medial femoral condyle in 5 knees, the lateral femoral condyle in 5 knees, and the femoral trochlea in 5 knees. The mean size of the lesion was 5.3 cm
2 . Each knee was clinically and radiologically evaluated preoperatively and postoperatively., Results: The mean Lysholm score improved significantly from 74.0 points to 94.0 points (p = 0.008) and each subscale in Knee injury and Osteoarthritis Outcome Score improved significantly (p < 0.001) at the mean final follow-up period of 51 months (range, 36-84 months). The magnetic resonance observation of cartilage repair tissue 2.0 score at the mean follow-up of 38 months was significantly higher than that at 2 months postoperatively (p = 0.014). According to the International Cartilage Repair Society (ICRS) grading scale, 3 knees were graded as normal, 3 knees as nearly normal, and 1 knee as severely abnormal in second-look arthroscopic evaluation at a mean of 22 months (range, 8-41 months) after A-ACI., Conclusion: The present study showed a significant subjective and objective clinical improvement in the A-ACI for large cartilage defects of the knee at a mean follow-up of 51 months (range, 36-84 months)., Competing Interests: Declaration of competing interest The authors declare no conflicts of interest associated with this manuscript., (Copyright © 2022 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
38. Horseshoe osteotomy maintains the nasal cavity and function after superior repositioning.
- Author
-
Kitagawa S, Habu M, Tsurushima H, Ohtani T, Sakamoto K, Yoshiga D, Yoshioka I, and Tominaga K
- Subjects
- Humans, Cephalometry, Maxilla diagnostic imaging, Maxilla surgery, Prospective Studies, Treatment Outcome, Nasal Cavity diagnostic imaging, Nasal Cavity surgery, Osteotomy, Le Fort methods
- Abstract
The aim of this prospective cohort study was to compare changes in nasal cavity and function between Le Fort I with and without horseshoe osteotomy after superior repositioning of the maxilla. The patients were divided into 2 groups, a Le Fort I alone (LF alone) group and a combination Le Fort I and horseshoe osteotomy (HS) group. The nasal cavity volume was measured using 3-dimensional computed tomographic images, and nasal resistance was assessed by anterior active mask rhinomanometry. The HS group consisted of 17 patients, and the LF alone group consisted of 15 patients. The magnitude of change in nasal cavity volume was significantly smaller in the HS group than in the LF alone group (p < 0.001), even though the mean amount of superior maxillary movement was considerably larger in the HS group than in the LF alone group (p < 0.001). Mean nasal resistance was significantly smaller postoperatively than preoperatively in the HS group (p < 0.05). Furthermore, the change in nasal resistance was smaller in the HS group than in the LF alone group (p < 0.001). Within the limitations of this study, it seems that horseshoe osteotomy is useful for maintaining the nasal cavity and function after superior repositioning of the maxilla., Competing Interests: Declaration of competing interest The authors report no conflict of interest., (Copyright © 2023 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
39. The impact of cystic duct tube on the onset time of postoperative bile leakage after hepatectomy: A propensity score-matched analysis.
- Author
-
Nagaoka T, Ogawa K, Sakamoto K, Tanaka K, Ito C, Iwata M, Sakamoto A, Nishi Y, Uraoka M, Shine M, Honjo M, Tamura K, Funamizu N, and Takada Y
- Subjects
- Humans, Cystic Duct, Postoperative Complications epidemiology, Postoperative Complications etiology, Postoperative Complications prevention & control, Bile, Propensity Score, Retrospective Studies, Drainage adverse effects, Hepatectomy adverse effects, Biliary Tract Diseases
- Abstract
Background: The cystic duct tube (C-tube) was used to reduce bile leakage (BL) incidence after hepatectomy. Nevertheless, delayed BL is sometimes experienced even using C-tube. This study investigates the impact of C-tube use on the onset time of post-hepatectomy BL., Methods: Data from 455 consecutive patients who underwent hepatectomy without biliary reconstruction between November 2007 and July 2020 were analyzed retrospectively. A C-tube was used for intraoperative biliary injury or in consideration of BL risk. BL was divided into two groups according to the postoperative onset time: early onset and late onset. To assess the association between C-tube use and BL, propensity score matching in a 1:1 ratio was performed to match BL risk factors between the C-tube and no-C-tube groups., Results: BL occurred in 30 (6.6%) of the 455 included patients. C-tubes were used in 51 patients (11.2%) with open hepatectomy, high-risk hepatectomy, massive blood loss, long operation time, or prophylactic drain placement. After propensity score matching, BL occurred in 17 of 102 patients (16.7%). Early-onset BL occurred significantly less frequently in the C-tube group than in the no-C-tube group (3.9% vs. 15.7%, p = 0.046); however, late-onset BL was more common in the C-tube group (9.8% vs. 3.9%, p = 0.24). Six of seven patients (85.7%) with BL with C-tube use developed BL after C-tube removal., Conclusion: C-tube drainage may reduce early-onset BL in cases having risk factors for BL. Conversely, since late-onset BL often occurs after C-tube removal, attention should be paid to those cases., Competing Interests: Declaration of competing interest None., (Copyright © 2023 Asian Surgical Association and Taiwan Robotic Surgery Association. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
40. Birth season and gross brain morphology associated with early neurodevelopment in schizophrenia spectrum patients and healthy subjects.
- Author
-
Takahashi T, Sasabayashi D, Takayanagi Y, Kobayashi H, Torigoe M, Sakamoto K, Yuasa Y, Tsujii N, Noguchi K, and Suzuki M
- Subjects
- Humans, Healthy Volunteers, Seasons, Brain diagnostic imaging, Brain pathology, Schizophrenia pathology, Schizotypal Personality Disorder pathology
- Abstract
This MRI study examined the effects of birth seasons on gross brain characteristics, such as the prevalence/size of midline brain structures (cavum septi pellucidi and adhesio interthalamica), orbitofrontal surface morphology, and insular gross anatomy, in 135 patients with schizophrenia, 47 with schizotypal disorder, and 88 healthy controls. Birth seasons only affected the insular anatomy. Summer-born subjects (N = 110) were characterized by more developed left insular gyri than winter-born subjects; however, this effect had no diagnostic specificity. The present results do not support birth seasons affecting the neurodevelopmental pathology of schizophrenia spectrum., Competing Interests: Declaration of Competing Interest There are no conflicts of interest to declare., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
41. Perioperative outcomes of open and robot-assisted partial nephrectomy in patients with renal tumors of moderate to high complexity.
- Author
-
Hori S, Sakamoto K, Onishi K, Tomizawa M, Morizawa Y, Gotoh D, Nakai Y, Miyake M, Torimoto K, Yoneda T, Tanaka N, and Fujimoto K
- Subjects
- Humans, Retrospective Studies, Treatment Outcome, Nephrectomy adverse effects, Robotics, Kidney Neoplasms pathology, Robotic Surgical Procedures adverse effects
- Abstract
Objective: To compare the perioperative outcomes of patients with complex renal tumors treated with open versus robot-assisted partial nephrectomy., Methods: This retrospective study included 273 patients diagnosed with localized renal tumors at our institution between January 2007 and October 2020. Patients with moderate to high complexity tumors based on the RENAL nephrometry score were included. Perioperative outcomes were compared between open and robot-assisted partial nephrectomy patients. Remnant renal function was defined as the estimated glomerular filtration rate at 12 months after surgery., Results: Open and robot-assisted partial nephrectomy were performed in 43 and 77 patients, respectively. There was no significant difference in overall, cancer-specific, recurrence-free, and metastasis-free survival between the two groups. Remnant renal function was significantly better preserved in the open group, and body mass index was identified as an independent predictive factor (odds ratio 3.05, P = 0.017). Ischemia or type of surgery were not related to remnant renal function. The trifecta achievement rate was 51.2% in the open group and 71.4% in the robot-assisted group (P = 0.031), and the incidence of complications was significantly higher in the open partial nephrectomy group (P = 0.0030). Multivariate analysis revealed that open partial nephrectomy was an independent predictive factor for the incidence of complications (odds ratio 3.92, P = 0.0020)., Conclusion: Robot-assisted partial nephrectomy can provide good and acceptable oncological and functional outcomes with fewer complications in patients with more complex renal tumors. Further research is needed to establish appropriate treatment strategies and guidelines in current clinical practice., Competing Interests: Declaration of competing interest The authors declare that they have no competing interests., (Copyright © 2023 Asian Surgical Association and Taiwan Robotic Surgery Association. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
42. Detection of impaired gas exchange using the 1-minute sit-to-stand test in patients with interstitial lung disease.
- Author
-
Oishi K, Asami-Noyama M, Yamamoto T, Matsumori K, Yonezawa K, Watanabe M, Hisamoto Y, Fukatsu A, Matsuda K, Hamada K, Suetake R, Ohata S, Murata Y, Yamaji Y, Sakamoto K, Ito K, Osoreda H, Edakuni N, Kakugawa T, Hirano T, and Matsunaga K
- Subjects
- Humans, Retrospective Studies, Lung, Respiratory Function Tests, Pulmonary Diffusing Capacity, Lung Diseases, Interstitial diagnosis
- Abstract
Background: Although pulmonary function tests (PFTs) are important in patients with interstitial lung disease (ILD), they cannot be easily performed in a primary healthcare setting. This study aimed to examine the usefulness of the difference between pulse oxygen saturation (SpO2) at rest and the lowest SpO2 during the 1-min sit-to-stand test (delta SpO2-1STST) for predicting pulmonary function impairment., Methods: We retrospectively reviewed 116 patients with ILD who underwent 1STST and PFTs., Results: The delta SpO2-1STST and diffusing capacity for carbon monoxide (DLco) strongly correlated (ρ = 0.70). The delta SpO2-1STST was effective in predicting impaired gas exchange (cut-off value, -4%; AUC, 0.86; sensitivity, 74%; specificity, 87%)., Conclusions: The Delta SpO2-1STST may be a reasonable tool for predicting abnormalities in PFTs., Competing Interests: Conflict of Interest K.O. reports the receipt of personal fees (honoraria) from Nippon Boehringer Ingelheim Co., Ltd. outside the submitted work. T.K. reports the receipt of personal fees (honoraria) from Nippon Boehringer Ingelheim Co., Ltd. outside the submitted work. K.M. (Kazuto Matsunaga) reports the receipt of personal fees (honoraria) from AstraZeneca K.K., GlaxoSmithKline K.K., Kyorin Pharmaceutical Co., Ltd., Novartis Pharma K.K., Nippon Boehringer Ingelheim Co., Ltd., and Sanofi K.K., outside the submitted work. The other authors have no conflicts of interest to declare., (Copyright © 2023 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
43. AlphaFold version 2.0 elucidates the binding mechanism between VIPR2 and KS-133, and reveals an S-S bond (Cys 25 -Cys 192 ) formation of functional significance for VIPR2.
- Author
-
Sakamoto K, Asano S, Ago Y, and Hirokawa T
- Subjects
- Humans, Mice, Animals, Vasoactive Intestinal Peptide metabolism, Cell Line, Receptors, Vasoactive Intestinal Peptide, Type II, Receptors, Vasoactive Intestinal Peptide metabolism
- Abstract
The vasoactive intestinal peptide receptor 2 (VIPR2) has attracted attention as a drug target for the treatment of mental disorders, cancer, and immune diseases. In 2021, we identified the peptide KS-133 as a VIPR2-selective antagonist. In this study, we aimed to elucidate the binding mechanism between VIPR2 and KS-133. To this end, VIPR2/KS-133 and VIPR2/vasoactive intestinal peptide (VIP) complex models were constructed through AlphaFold version 2.0 and molecular dynamic simulations. Our models revealed that: (i) both KS-133 and VIP have helical structures, (ii) the interaction residues on VIPR2 for both peptides are similar, and (iii) the orientation of their helices upon their binding to VIPR2 are different by ∼45°. Interestingly, in the process of constructing the aforementioned models, an S-S bond formation between Cys
25 and Cys192 of the human VIPR2 was identified. Although these two Cys residues are highly conserved among species (i.e., corresponding to Cys24 and Cys191 in the mouse), no previous reports regarding this S-S bond formation exist. In order to clarify the potential role of this S-S bond in the VIPR2 has functional consequences, a cell line expressing the mouse VIPR2(Cys24Ala, Cys191Ala) was generated. During the VIP stimulation of this cell line, the phosphorylation of AKT (a downstream signal marker of VIPR2) was found to be significantly attenuated, thereby suggesting that the S-S bond has a functional significance for VIPR2. Our study not only elucidates the VIPR2-binding mechanism of KS-133 for the first time, but also provides new insights into the structural biology of VIPR2., Competing Interests: Declaration of competing interest This research received no external funding. The author has no conflict of interest to declare., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
44. Administration of the antiviral agent T-1105 fully protects pigs from foot-and-mouth disease infection.
- Author
-
Nishi T, Fukai K, Masujin K, Kawaguchi R, Ikezawa M, Yamada M, Nakajima N, Komeno T, Furuta Y, Sugihara H, Kurosaki C, Sakamoto K, and Morioka K
- Subjects
- Swine, Animals, Antiviral Agents therapeutic use, Pyrazines pharmacology, Foot-and-Mouth Disease drug therapy, Foot-and-Mouth Disease prevention & control, Foot-and-Mouth Disease Virus
- Abstract
Foot-and-mouth disease (FMD) is a contagious disease affecting cloven-hoofed animals. Its transmissibility and antigenic variety make this disease difficult to control. Antiviral agents are expected to have an immediate effect that is independent of viral antigenicity; thus, they can serve as effective tools for inhibiting the spread of the causative agent, the FMD virus (FMDV), from infected animals. In this study, we investigated the antiviral activity of a pyrazinecarboxamide derivative, T-1105, against FMDV. Cytopathic effect inhibition assays revealed that T-1105 strongly inhibited the replication of 28 reference strains of all seven FMDV serotypes at non-cytotoxic concentrations. The antiviral effect of T-1105 against FMDV was also evaluated by experimental infection of domestic pigs. T-1105 was administered orally to pigs starting 1 h before or 6 h after the inoculation of a porcinophilic FMDV serotype O, topotype CATHAY. None of the pigs administered with T-1105 showed clinical signs of FMD. Moreover, no infectious FMDVs or FMDV-specific genes were detected in their sera, oral and nasal discharges, or tissues collected 48 h after virus inoculation. These findings strongly suggest that administration of T-1105 is effective in controlling the spread of FMDV in pigs., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
45. The Double-Stranded RNA Analog, Poly(I:C), Triggers Distinct Transcriptomic Shifts in Keratinocyte Subsets.
- Author
-
Sakamoto K and Nagao K
- Subjects
- Keratinocytes, Transcriptome, Poly I-C pharmacology, RNA, Double-Stranded genetics
- Published
- 2022
- Full Text
- View/download PDF
46. Autonomic nerve activity and cardiovascular changes during discrete seizures in rats.
- Author
-
Naggar I, Sakamoto K, Jones S, and Stewart M
- Subjects
- Animals, Bradycardia, Heart, Heart Rate physiology, Rats, Vagus Nerve, Electroencephalography adverse effects, Seizures chemically induced
- Abstract
Activity in both divisions of the autonomic nervous system (ANS) can increase during seizures and result in tachy- or bradyarrhythmias. We sought to determine the patterns of ANS activity that led to heart rate (HR) changes and whether the character of ANS and HR changes can impact the seizures themselves. Simultaneous recordings of vagus nerve and cervical sympathetic ganglionic or nerve activity, EEG, ECG, and blood pressure were acquired from 16 urethane-anesthetized rats that received systemic kainic acid to induce seizures. After initial continuous seizure activity, discrete seizures were observed in 11/16 rats. Individual seizures were classified based on HR changes as tachycardic (n = 3), bradycardic (n = 17), or one of two more severe categories in which (a) the seizure appeared to be terminated by severe bradyarrhythmia (n = 5) or (b) the animal died (n = 6). Interestingly, even simple bradycardic seizures had episodes of dramatically increased respiratory effort, which we interpret as evidence of airway occlusion based on muscle artifacts in the recordings with transient blood pressure decreases. In the severe outcomes, ANS activity increased during seizures until it caused a drastic HR reduction (>50%), in which case seizure and ANS activity decreased dramatically. Sympathetic activity during this late vulnerable period was important for survival. We conclude that individual seizures produce (a) stereotypical changes in autonomic activity and HR, (b) persistence of sympathetic tone helps to protect against death, and (c) bradycardic seizures may indicate increased risk for seizure-associated obstructive apnea., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
47. Surgery for intractable epilepsy after severe encephalopathy with reversible splenial lesion and new onset hippocampal lesion associated with parechovirus.
- Author
-
Iimura Y, Nakazawa M, Suzuki H, Mitsuhashi T, Ueda T, Sakamoto K, Nishioka K, Horikoshi K, and Sugano H
- Subjects
- Child, Child, Preschool, Corpus Callosum pathology, Corpus Callosum surgery, Female, Fever complications, Hippocampus diagnostic imaging, Hippocampus pathology, Hippocampus surgery, Humans, Magnetic Resonance Imaging adverse effects, Seizures etiology, Syndrome, Brain Diseases pathology, Drug Resistant Epilepsy complications, Drug Resistant Epilepsy surgery, Encephalitis complications, Epilepsy complications, Parechovirus, Status Epilepticus complications, Status Epilepticus surgery
- Abstract
We describe a case of severe encephalopathy with reversible splenial lesion associated with parechovirus, followed by intractable temporal lobe epilepsy (TLE), which was improved by epilepsy surgery. A 3-year-old girl was admitted because of fever, consciousness disturbance and generalized tonic clonic seizure. Her seizure lasted for four hours. Fluid-attenuated inversion recovery (FLAIR) showed a hyperintensity in the splenium of the corpus callosum. Electroencephalogram (EEG) demonstarated continuous diffuse epileptic activity represented by synchronous and rhythmic high-amplitude spikes and waves, which led to the diagnosis of status epilepticus. Her consciousness was improved with fosphenytoin, midazolam and methylprednisolone pulse after 3 days. Seven days later, FLAIR hyperintensity in the splenium of the corpus callosum was disappeared; however, a hyperintensity in the right hippocampus was detected. Since the stool examination was positive for parechovirus, her final diagnosis was reversible splenial lesion syndrome (RESLES) associated with parechovirus. At age 8, she experienced epigastric sensation and consciousness disturbance once a week. Based on the scalp EEG and radiological findings, she was diagnosed with intractable right TLE. We performed a right selective amygdalohippocampectomy and anterior temporal disconnection at 10 years of age. One year and 3 months after surgery, she was seizure free. To our knowledge, this is the first report of severe febrile epilepticus status. with RESLES associated with parechovirus, followed by intractable TLE, which was resolved by epilepsy surgery., Competing Interests: Conflict of interest disclosures The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper., (Copyright © 2022 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
48. The mammalian-type thioredoxin reductase 1 confers a high-light tolerance to the green alga Chlamydomonas reinhardtii.
- Author
-
Asahina Y, Sakamoto K, Hisabori T, and Wakabayashi KI
- Subjects
- Algal Proteins metabolism, Animals, CRISPR-Cas Systems, Chlamydomonas reinhardtii enzymology, Chlamydomonas reinhardtii radiation effects, Gene Editing methods, Gene Knockout Techniques, Hydrogen Peroxide pharmacology, Mammals genetics, Mammals metabolism, Oxidants pharmacology, Photosynthesis genetics, Photosynthesis radiation effects, Phototaxis drug effects, Phototaxis radiation effects, RNA-Seq methods, Reactive Oxygen Species metabolism, Thioredoxin Reductase 1 metabolism, Algal Proteins genetics, Chlamydomonas reinhardtii genetics, Light, Radiation Tolerance genetics, Thioredoxin Reductase 1 genetics
- Abstract
Reactive oxygen species (ROS) can both act as a poison causing cell death and important signaling molecules among various organisms. Photosynthetic organisms inevitably produce ROS, making the appropriate elimination of ROS an essential strategy for survival. Interestingly, the unicellular green alga Chlamydomonas reinhardtii expresses a mammalian form of thioredoxin reductase, TR1, which functions as a ROS scavenger in animal cells. To investigate the properties of TR1 in C. reinhardtii, we generated TR1 knockout strains using CRISPR/Cas9-based genome editing. We found a reduced tolerance to high-light and ROS stresses in the TR1 knockout strains compared to the parental strain. In addition, the regulation of phototactic orientation, known to be regulated by ROS, was affected in the knockout strains. These results suggest that TR1 contributes to a ROS-scavenging pathway in C. reinhardtii., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
49. Clinical outcomes of corticosteroids for COVID-19 patients at the National Center for Global Health and Medicine during the first wave of infections.
- Author
-
Morita C, Suzuki M, Izumi S, Tsukada A, Tsujimoto Y, Sakamoto K, Hashimoto M, Takasaki J, Ohmagari N, and Hojo M
- Subjects
- Adrenal Cortex Hormones, Global Health, Humans, Retrospective Studies, SARS-CoV-2, COVID-19
- Abstract
Background: Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2, has been a significant concern worldwide since its outbreak in December 2019. Various treatments are being researched and developed, and there are reports that dexamethasone has reduced the mortality rate and improved the clinical course of critically ill patients with COVID-19. In this study, we examined the clinical efficacy of corticosteroid therapy for patients with COVID-19 in our hospital during the first wave of infections., Methods: We retrospectively reviewed the medical records of patients with COVID-19 who were treated with or without corticosteroid therapy at the National Center for Global Health and Medicine in Japan between February and April 2020. The primary outcome was improvement in the patients' clinical course using a seven-category ordinal scale. We collected data on patient characteristics, treatment, and clinical course, and compared them between two groups: the steroid-using group and the non-steroid-using group., Results: Between February and April 2020, 110 patients were diagnosed with COVID-19. Despite poor conditions during admission into the steroid group, there were no statistical differences in clinical course between both groups, as measured using the scale. There were no statistical differences between the two groups in the number of days to fever resolution or negative polymerase chain reaction results., Conclusions: There was no difference in the clinical course between both groups. Because of the difference in background, corticosteroids may potentially make the clinical course of severely ill patients similar to that of mildly ill patients., Competing Interests: Conflict of Interest Yoshie Tsujimoto received research grants from Roche Diagnostic Inc. Masayuki Hojo received Honoraria from AstraZeneca, GlaxoSmithKline, Novartis Pharma, and Boehringer Ingelheim. Chie Morita, Manabu Suzuki, Shinyu Izumi, Akinari Tsukada, Keita Sakamoto, Masao Hashimoto, Jin Takasaki, and Norio Ohmagari have no conflict of interest., (Copyright © 2021 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
50. Successfully treated bronchopulmonary oxalosis caused by Aspergillus tubingensis in a non-neutropenic patient: A case report and review of the literature.
- Author
-
Hase I, Kagatani J, Suzuki S, Yoshida S, Sakamoto K, Maitani F, Horinouchi H, Kamei K, and Tateno H
- Subjects
- Aspergillus genetics, Humans, Microbial Sensitivity Tests, Antifungal Agents therapeutic use, Hyperoxaluria drug therapy
- Abstract
Pulmonary oxalosis can be fatal, and Aspergillus tubingensis is commonly resistant to azoles in Japan. We report a case of bronchopulmonary oxalosis caused by A. tubingensis in a non-neutropenic patient who was successfully treated with voriconazole monotherapy. The susceptibility of the isolates to voriconazole and the effective elimination of contagious necrotic tissue by expectoration seemed to be two major factors contributing to the patient's survival. According to the literature review, pulmonary oxalosis is associated with a high mortality rate over a short term. An exploration of detailed information about the genomic characteristics and drug susceptibility of Aspergillus isolates is important for the development of treatment strategies for this life-threatening disease., (Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.